Teva Pharma Industries Stock Fundamentals
| TEVA Stock | USD 17.84 0.70 3.78% |
Teva Pharma Industries fundamentals help investors to digest information that contributes to Teva Pharma's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharma stock.
At present, Teva Pharma's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 1.2 B, whereas Total Revenue is forecasted to decline to about 9.7 B. Teva | Select Account or Indicator |
Teva Pharma Industries Company Return On Equity Analysis
Teva Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Teva Pharma Return On Equity | -0.18 |
Most of Teva Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharma Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Teva Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Teva Pharma Industries has a Return On Equity of -0.1752. This is 99.27% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United States stocks is 43.48% lower than that of the firm.
Teva Pharma Industries Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Teva Pharma's current stock value. Our valuation model uses many indicators to compare Teva Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Teva Pharma competition to find correlations between indicators driving Teva Pharma's intrinsic value. More Info.Teva Pharma Industries is rated below average in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, Teva Pharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Teva Pharma's earnings, one of the primary drivers of an investment's value.Teva Pharma's Earnings Breakdown by Geography
Teva Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Teva Pharma could also be used in its relative valuation, which is a method of valuing Teva Pharma by comparing valuation metrics of similar companies.Teva Pharma is currently under evaluation in return on equity category among its peers.
Teva Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Teva Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Teva Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Teva Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0556 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 36.06 B | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Institutions | 58.22 % | ||||
| Number Of Shares Shorted | 15.8 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.91 X | ||||
| Price To Sales | 1.26 X | ||||
| Revenue | 16.54 B | ||||
| Gross Profit | 8.36 B | ||||
| EBITDA | (303 M) | ||||
| Net Income | (1.96 B) | ||||
| Cash And Equivalents | 2.22 B | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 20.15 B | ||||
| Debt To Equity | 2.27 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 5.35 X | ||||
| Cash Flow From Operations | 1.25 B | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (1.45) X | ||||
| Price To Earnings To Growth | 1.04 X | ||||
| Target Price | 25.06 | ||||
| Number Of Employees | 37 K | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 21.2 B | ||||
| Total Asset | 43.48 B | ||||
| Retained Earnings | (13.53 B) | ||||
| Working Capital | 238 M | ||||
| Current Asset | 18.4 B | ||||
| Current Liabilities | 13.01 B | ||||
| Five Year Return | 2.95 % | ||||
| Net Asset | 43.48 B |
About Teva Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharma Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharma Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5.7 B | 3.1 B | |
| Total Revenue | 16.5 B | 9.7 B | |
| Cost Of Revenue | 8.5 B | 4.8 B | |
| Sales General And Administrative To Revenue | 0.07 | 0.05 | |
| Research And Ddevelopement To Revenue | 0.06 | 0.05 | |
| Capex To Revenue | 0.04 | 0.07 | |
| Revenue Per Share | 12.76 | 7.88 | |
| Ebit Per Revenue | 0.03 | 0.03 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out Teva Pharma Piotroski F Score and Teva Pharma Altman Z Score analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.